(Date:11/23/2009)...e-FirstCall/--PDLBioPharma,Inc.(PDL)(Nasdaq: PDLI ...2009astheex-dividenddateforits$200millionspecialdi...transactioncompletedonNovember2,2009.Thedividendwi...ontherecorddate,December1,2009.NASDAQhassettheappr...fcommonstockforpurposesoftheex-dividenddateonNovem...
(Date:11/23/2009)...signC or p.(IDC)announcedtodaythatDr.BruceL.A.Cart...cessfultrackrec or dinbiotechnologyexecutivemanage...netics,inSeattle,WAandChiefScientificOfficeratNovo.../www.newscom.com/cgi-bin/prnh/20091123/SF15228 ) ,...ficercommented,"IamdelightedtowelcomeDr.BruceCarte...
(Date:11/23/2009)...l/--CornerstoneTherapeuticsInc.(Nasdaq: CRTX ),asp...elopingandcommercializingsignificantproductsprimar...edthatCraigA.Collard,PresidentandChiefExecutiveOff...nualPiperJaffrayHealthCareConferenceat3:30PMETonWe...YorkCity. ,, AliveaudioandarchivedwebcastofCorn...
(Date:11/20/2009)...stCall/ -- Dendreon Corporation (Nasdaq: DNDN ) t...tration (FDA) provided written acknowledgement tha...ion (BLA) for PROVENGE® (sipuleucel-T) is a c...tion Drug User Fee Act (PDUFA) date of May 1, 2010...ded BLA. Dendreon is seeking licensure for PROVEN...
Breaking Biology Technology:PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director 2Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference 2Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3...- No Material Impact on Business Expected -, HOUS...ay announced that, based on an initial assessment,...d no damage as a result of Hurricane,Ike., Howeve...eral more days.,Therefore, the Company is currentl..., Cyberonics maintains sufficient product invento...
...WALTHAM, Mass., Sept. 15 Inverness Medical,Innova...ear-patient,diagnostics, monitoring and health man....77 per share on its Series B Convertible Perpetua...ill be paid in shares of Series B,stock in an amou...vided by,(b) 97% of the average of the volume-weig...
...SAN MARINO, Calif., Sept. 15 Epeius Biotechnologi...ead product in development,for metastatic cancer, ...ished by the Journal of the National Cancer Instit... Vickie Brower, describes recent advances,and new ...ere small,molecules and proteins have failed. Note...
Other Biology Technology:Cyberonics Provides Update on Business Operations Following Hurricane Ike 2Cyberonics Provides Update on Business Operations Following Hurricane Ike 3Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock 2Epeius Biotechnologies' Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal 2Rabbit Anti-C/EBPalpha Polyclonal Antibody, Unconjugated from Cell Signaling Technology
Rabbit Anti-Human VEZT Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Ia Antigen Monoclonal Antibody, Biotin Conjugated, Clone CIa from Abcam
Rabbit Anti-TAK1, phospho (Thr184 / Thr187) Monoclonal Antibody, Unconjugated, Clone 90C7 from Cell Signaling Technology
Biology Products: